Related Experiment Video
Updated: Sep 26, 2026

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
Beta-thalassemia intermedia in a Brazilian patient with-101 (C > T) and codon 39 (C > T) mutations
Sylvia Morais de Sousa1, Letícia Khater, Luis Antônio Peroni
1Centro de Biologia Molecular Estrutural e Engenharia Genética, Hemocentro, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil. smsoursa@unicamp.br
Context:
We verified molecular alterations in a 72-year-old Brazilian male patient with a clinical course of homozygous beta-thalassemia intermedia, who had undergone splenectomy and was surviving without regular blood transfusions. The blood cell count revealed microcytic and hypochromic anemia (hemoglobin = 6.5 g/dl, mean cell volume = 74 fl, mean cell hemoglobin = 24 pg) and hemoglobin electrophoresis showed fetal hemoglobin = 1.3%, hemoglobin A2 = 6.78% and hemoglobin A = 79.4%.
Objective:
To identify mutations in a patient with the symptoms of beta-thalassemia intermedia.
Design:
Molecular inquiry into the mutations possibly responsible for the clinical picture described.
Setting:
The structural molecular biology and genetic engineering center of the Universidade Estadual de Campinas, Campinas, Brazil.
Procedures:
DNA extraction was performed on the patient's blood samples. The polymerase chain reaction (PCR) was done using five specific primers that amplified exons and the promoter region of the beta globin gene. The samples were sequenced and then analyzed via computer programs.
Results:
Two mutations that cause the disease were found: -101 (C > T) and codon 39 (C > T).
Conclusions:
This case represents the first description of -101 (C > T) mutation in a Brazilian population and it is associated with a benign clinical course.
Related Concept Videos
Translation
Translation
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Mutations
